Bulge oligonucleotide as an inhibitory agent of bacterial topoisomerase I

Zhaoqi Yang, Tuoyu Jiang, Hanshi Zhong, Yu KangJournal of Enzyme Inhibition and Medicinal Chemistry 2017 · DOI

TL;DR

Researchers have developed novel bulge-containing DNA oligonucleotides that effectively inhibit bacterial topoisomerase I (Btopo I), a key target for antibacterial drugs. These synthetic molecules show high potency and specificity, irreversibly damaging Btopo I without affecting its eukaryotic counterpart, offering a promising new avenue for antibiotic development.

What Problem Does This Paper Address?

Bacterial topoisomerase I (Btopo I) is a crucial enzyme for bacterial DNA replication, transcription, and repair, making it an attractive target for new antibacterial agents. While existing antibacterial treatments like quinolones target Btopo I, there's a continuous need for novel therapeutic strategies to combat rising antibiotic resistance. Previous research has shown that certain modified DNA structures, like those with gaps or nicks, can irreversibly inhibit eukaryotic topoisomerase I. This paper explores whether similar non-supercoiled DNA structures, specifically those with a "bulge" (a small loop of unpaired bases within a double-stranded DNA segment), could act as effective and specific inhibitors of bacterial topoisomerase I. The challenge is to design molecules that can specifically target and inactivate Btopo I without harming essential human enzymes.

Methods

The core of this study involved the design and synthesis of several bulge-containing double-stranded DNA oligonucleotides. These oligonucleotides were engineered to mimic certain DNA structures that Btopo I can interact with, specifically by introducing a single-stranded loop (the "bulge") within an otherwise double-stranded DNA molecule.

The primary experimental technique used was an in vitro topoisomerase relaxation assay. This assay uses supercoiled plasmid DNA (pUC19) as a substrate. Topoisomerase I enzymes normally relax this supercoiled DNA into a relaxed form. The researchers then introduced their designed bulge oligonucleotides into the reaction mixture to see if they could inhibit this relaxation activity.

  • Bacterial Topoisomerase I (Btopo I) Inhibition Assay: Supercoiled pUC19 DNA was incubated with Btopo I in the presence or absence of the designed bulge oligonucleotides. The extent of DNA relaxation was then analyzed by gel electrophoresis. The degree to which relaxation was inhibited indicated the effectiveness of the bulge oligonucleotide as an inhibitor.
  • Eukaryotic Topoisomerase I Specificity Assay: To confirm the specificity of the inhibitors, the same relaxation assay was performed using eukaryotic topoisomerase I (from calf thymus) as a control.
  • IC<sub>50</sub> Determination: For the most effective inhibitors, a dose-response experiment was conducted to determine the half-maximal inhibitory concentration (IC<sub>50</sub>), which quantifies the concentration of inhibitor needed to reduce enzyme activity by 50%.
  • Irreversibility Assay: To investigate if the inhibition was permanent, the researchers performed a time-course experiment where the incubation time was extended in the presence of the most potent inhibitor.

Datasets

Not discussed in the paper. The study utilized commercially available plasmid DNA (pUC19) and purified bacterial and eukaryotic topoisomerase I enzymes. The synthesized oligonucleotides served as the experimental "datasets" for testing.

Key Insights and Ideas

  • Bulge Structure as a Potent Inhibitor: The introduction of a bulge structure into double-stranded oligonucleotides proved to be a highly effective strategy for inhibiting bacterial topoisomerase I. This suggests that Btopo I can recognize and interact with these non-canonical DNA structures.
  • Length Matters: The inhibitory efficiency of the bulge oligonucleotides was directly correlated with the length of the single-stranded loop (the bulge). Longer bulges led to stronger inhibition, indicating a tunable mechanism for designing more potent inhibitors.
  • Irreversible Damage: The most effective bulge oligonucleotide (B-1-10) caused irreversible damage to Btopo I. This suggests that the enzyme might become covalently trapped or permanently altered, leading to its inactivation.
  • Bacterial Specificity: Crucially, the designed bulge oligonucleotides showed no inhibitory effect on eukaryotic topoisomerase I. This high specificity is vital for developing therapeutic agents that target bacterial pathogens without causing harm to host cells.

Key Results

  • The designed bulge oligonucleotides demonstrated significant inhibitory effects on Btopo I activity.
  • The most potent inhibitor, B-1-10, achieved an IC<sub>50</sub> value of 63.1 nM, indicating high efficacy at low concentrations.
  • Inhibition increased with the length of the bulge loop, with B-1-10 (longest loop) being the most effective.
  • Time-course experiments showed that B-1-10 caused a persistent inhibition of Btopo I, suggesting irreversible inactivation.
  • Eukaryotic topoisomerase I was not inhibited by any of the tested bulge oligonucleotides, highlighting their selective targeting of bacterial enzymes.

Limitations and Future Work

  • Delivery into Bacteria: The authors acknowledge that a significant challenge for oligonucleotide-based therapeutics is their efficient delivery into bacterial cells. They express hope that advancements in nanotechnology and pharmaceutics will overcome this hurdle.
  • Mechanism of Irreversible Damage: While irreversibility was demonstrated, the precise molecular mechanism by which the bulge oligonucleotides cause permanent damage to Btopo I warrants further investigation.
  • In Vivo Efficacy: The study was conducted in vitro. Future work would need to evaluate the in vivo antibacterial efficacy and safety of these bulge oligonucleotides in relevant model systems.
  • Optimization: Further optimization of bulge structure, length, and chemical modifications could potentially lead to even more potent and specific inhibitors.

Summary updated

Abstract

Bacterial topoisomerase I (Btopo I) was defined as potential target for discovery of new antibacterial compounds. Various oligonucleotides containing bulge structure were designed and synthesised as inhibitors to Btopo I in this investigation. The results of this study demonstrated that the designed oligonucleotides display high inhibitory efficiency on the activity of Btopo I and the inhibitory effect could be modulated by the amount of bulge DNA bases. The most efficient one among them showed an IC<sub>50</sub> value of 63.1 nM in its inhibition on the activity of Btopo I. In addition, our studies confirmed that the designed oligonucleotide would induce irreversible damages to Btopo I and without any effects occur to eukaryotic topoisomerase I. It is our hope that the results provided in these studies could provide a novel way to inhibit Btopo I.
BibTeX
@article{yang2017bulge,
  author = {Zhaoqi Yang and Tuoyu Jiang and Hanshi Zhong and Yu Kang},
  title = {{Bulge oligonucleotide as an inhibitory agent of bacterial topoisomerase I}},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2017},
  doi = {10.1080/14756366.2017.1419218},
}
Figure